Leerink Partnrs Weighs in on NRIX Q3 Earnings

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Equities researchers at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for Nurix Therapeutics in a report released on Monday, March 17th. Leerink Partnrs analyst F. Khurshid anticipates that the company will earn ($0.96) per share for the quarter. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is ($2.99) per share. Leerink Partnrs also issued estimates for Nurix Therapeutics’ Q4 2025 earnings at ($1.00) EPS, FY2025 earnings at ($3.79) EPS and FY2026 earnings at ($3.32) EPS.

Several other analysts also recently commented on the company. Morgan Stanley upped their price objective on Nurix Therapeutics from $16.00 to $17.00 and gave the company an “equal weight” rating in a research note on Monday, February 3rd. BTIG Research assumed coverage on Nurix Therapeutics in a research note on Tuesday, December 10th. They set a “buy” rating and a $35.00 price target for the company. Stephens reaffirmed an “overweight” rating and set a $31.00 price target on shares of Nurix Therapeutics in a report on Tuesday, January 21st. HC Wainwright boosted their price objective on shares of Nurix Therapeutics from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Finally, Leerink Partners began coverage on shares of Nurix Therapeutics in a research note on Monday, March 17th. They issued a “market perform” rating and a $16.00 target price for the company. Three research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $30.88.

Nurix Therapeutics Stock Performance

Shares of NASDAQ:NRIX opened at $12.99 on Thursday. Nurix Therapeutics has a one year low of $11.90 and a one year high of $29.56. The company has a 50-day simple moving average of $17.00 and a 200-day simple moving average of $20.80. The stock has a market capitalization of $985.77 million, a price-to-earnings ratio of -4.49 and a beta of 2.18.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%.

Insider Activity

In other news, CFO Houte Hans Van sold 2,811 shares of the firm’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $55,798.35. Following the completion of the transaction, the chief financial officer now owns 39,549 shares in the company, valued at $785,047.65. This trade represents a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Gwenn Hansen sold 3,690 shares of the business’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $73,246.50. Following the completion of the sale, the insider now owns 55,937 shares in the company, valued at $1,110,349.45. This represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 12,326 shares of company stock worth $213,449. Company insiders own 7.20% of the company’s stock.

Hedge Funds Weigh In On Nurix Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NRIX. US Bancorp DE raised its position in Nurix Therapeutics by 144.7% during the fourth quarter. US Bancorp DE now owns 1,424 shares of the company’s stock worth $27,000 after acquiring an additional 842 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Nurix Therapeutics during the fourth quarter worth about $28,000. Quarry LP raised its position in Nurix Therapeutics by 3,746.2% during the third quarter. Quarry LP now owns 2,500 shares of the company’s stock worth $56,000 after acquiring an additional 2,435 shares during the last quarter. Aquatic Capital Management LLC acquired a new position in Nurix Therapeutics during the fourth quarter worth about $87,000. Finally, Summit Investment Advisors Inc. raised its position in Nurix Therapeutics by 13.6% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company’s stock worth $138,000 after acquiring an additional 877 shares during the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.